Clinical trials: Herpes Simplex Virus 2
Viral Hepatitis Vaccines, Hepatitis A
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV), Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella pertussis (BP)infections in Mexico.
- Conditions
- Viral Hepatitis Vaccines, Hepatitis A, Cytomegalovirus, Varicella-Zoster Virus
- Trial name
- NCT01160081
- Testing
- Serum sample
- Where
- Mexico
- Volunteers
- 3,658 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Simplex
Herpevac Neonatal Substudy
The purpose of this study to look at the antibodies (proteins from the body's infection fighting system) in the blood of babies delivered by women who are participants in the Herpevac Trial for Women, and who were vaccinated with…
- Trial name
- NCT00138320
- Where
- 5 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Stepping Stones Program for Preventing HIV Infection in Residents of Rural South African Communities
This study will evaluate the effectiveness of Stepping Stones, an HIV-prevention education program, versus a brief HIV-focused intervention, in improving sexual health and preventing HIV infection in young residents of rural…
- Trial name
- NCT00332878
- Testing
- Stepping Stones, stepping Stones short
- Where
- South Africa
- Volunteers
- 2,801 people, healthy volunteers welcome
- Sponsor
- Medical Research Council, South Africa
HIV
An Assessment of an HIV Prevention Intervention (Project AIM) Among Junior Secondary School Students in Eastern Botswana
The purpose of this study is to examine the effectiveness of an HIV prevention intervention called Project AIM (Adult Identity Mentoring) to delay onset of sexual activity and reduce sexual risk behaviors among students…
- Trial name
- AIM (NCT02455583)
- Testing
- Project AIM (Adult Identity Mentoring)
- Where
- Botswana
- Volunteers
- 4,732 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Herpes Simplex 2, Meningitis, Viral
Aciclovir Versus Placebo for HSV-2 Meningitis
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
- Trial name
- AMEN (NCT05452928)
- Testing
- Acyclovir 50 MG/ML
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Jacob Bodilsen
Herpes Simplex Keratitis
The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)
The aim of this study is to compare the safety, specificity, sensitivity and ease of procedure of two potential diagnostic assays for HSV-1 detection in the cornea.
- Trial name
- NCT00357812
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Ulster
HIV
School Support as Structural HIV Prevention for Adolescent Orphans in Kenya
The purpose of this study is to test whether school support can keep adolescent Kenyan orphans in school, reduce sexual risk behaviors, and prevent HIV /HSV-2 infection.
- Trial name
- NCT01501864
- Testing
- School Support Intervention
- Where
- 2 sites in United States, Kenya
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- Pacific Institute for Research and Evaluation
Genital Herpes
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
The purposes of this study are: To determine the accuracy of commercially available serologic assays in diagnosing patients with herpes simplex virus type 2 (HSV-2); To assess the sensitivity and specificity of the commerical…
- Trial name
- NCT01112956
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, Sexually Transmitted Diseases
Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
This randomized controlled trial conducted in Rakai District, Uganda, has enrolled 997 HIV positive men and 500 men who declined to learn HIV results (regardless of HIV status).
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Papillomavirus Infections, Genital Herpes
- Trial name
- NCT00124878
- Testing
- Male circumcision
- Where
- Uganda
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- Wawer, Maria J., M.D.
HIV Infections, Gonorrhea
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydial Infections, Genital Herpes
- Trial name
- NCT00262106
- Testing
- PRO 2000/5
- Where
- 6 sites in South Africa, Tanzania and 2 more
- Volunteers
- 9,404 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
HIV Infections, Herpesvirus 2, Human
Male Circumcision for HIV Prevention in Rakai, Uganda
Circumcision in HIV unifected men may reduce the likelihood of becoming infected with HIV, reduce sexually transmitted infections (STIs) in men, not engender increases in sexual risk behaviors, and be acceptable to men as a…
- Conditions
- HIV Infections, Herpesvirus 2, Human, Syphilis, Genital Diseases, Male
- Trial name
- NCT00425984
- Testing
- Adult male circumcision
- Where
- Uganda
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Simplex
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine
Evaluate, one month after the third dose, the lot-to-lot consistency of 3 different commercial scale production lots of the candidate vaccine in healthy HSV 1-/2- females aged 10-17 years, determined by ELISA.
- Trial name
- NCT00224471
- Testing
- GSK208141 vaccine
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 671 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline